Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 30 days matching "hemophilia inhibitors"

Clinical trialRSSMay 8

Denecimig excels at reducing bleeds in hemophilia A patients: Study

A new medicine called denecimig (Mim8) was tested in a study called FRONTIER2 and worked better than current treatments at stopping bleeding episodes in people with hemophilia A. The medicine was given either once a month or once a week, and it worked well for both adults and teenagers 12 years and older, even for patients whose bodies have developed resistance to other treatments.

WHY IT MATTERSIf denecimig gains approval, hemophilia A patients—especially those with inhibitors who have limited treatment options—could switch to a once-monthly injection that reduces bleeds more effectively than their current preventive regimens.
💬 Ask your doctorhemophilia Ahemophilia A with inhibitors
Clinical trialRSSApr 28

FX activator may help with bleeding control in hemophilia A and B: Trials

Researchers tested a new medicine called bemiltenase alfa that helps control bleeding in people with hemophilia A and B. These patients had developed resistance to standard treatments, making their bleeding harder to manage. Early trial results show this new medicine may help them control bleeding when it happens.

WHY IT MATTERSFor hemophilia patients who have developed inhibitors (antibodies that block standard treatments), bemiltenase alfa offers a potential new option for on-demand bleeding control when current therapies no longer work effectively.
💬 Ask your doctorHemophilia AHemophilia B
Clinical trialRSSApr 24

Single infusion of Roctavian linked to fewer bleeds in hemophilia A

A new treatment called Roctavian was given as a single injection to men with severe hemophilia A (a bleeding disorder). Seven years later, most patients had fewer bleeding episodes and needed less preventive medicine. This suggests the treatment's benefits can last for many years.

WHY IT MATTERSIf you have severe hemophilia A, Roctavian could mean switching from frequent infusions or injections to a single treatment that protects you from bleeds for years.
💬 Ask your doctorHemophilia A

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases